Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Terminated 8Recruiting 7Active not recruiting 5Completed 4Unknown 2Withdrawn 1

Sponsor Class

OTHER 13INDUSTRY 5NIH 2NETWORK 1

Study Type

Interventional 4Observational 1

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 2Thoracic 1Myeloid 1Genitourinary 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 298Neoplasms 179Breast Neoplasms 169Colorectal Neoplasms 107Neoplasm Metastasis 99Melanoma 99Multiple Myeloma 93Prostatic Neoplasms 90Ovarian Neoplasms 83Recurrence 79Carcinoma, Renal Cell 73Lung Neoplasms 71Stomach Neoplasms 67Squamous Cell Carcinoma of Head and Neck 66Lymphoma, Non-Hodgkin 61Pancreatic Neoplasms 59Leukemia, Lymphocytic, Chronic, B-Cell 56Leukemia, Myeloid, Acute 54Carcinoma, Hepatocellular 48Triple Negative Breast Neoplasms 46Urinary Bladder Neoplasms 45Small Cell Lung Carcinoma 45Lymphoma, Large B-Cell, Diffuse 43Head and Neck Neoplasms 41Endometrial Neoplasms 41Lymphoma, Follicular 39Lymphoma 37Uterine Cervical Neoplasms 35Parkinson Disease 4, Autosomal Dominant Lewy Body 34Glioblastoma 34

Interventions

blinatumomab 2tisagenlecleucel 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × INDUSTRY × Neoplasm, Residual × Clear all
NCT03876769 2026-06-02

CASSIOPEIA

Novartis

Phase 2 Active not recruiting
121 enrolled
Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT04521231 2026-05-28

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

Amgen

Phase 1/2 Active not recruiting
181 enrolled
LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07134088 2026-05-15

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Amgen

Phase 1/2 Active not recruiting
104 enrolled
Lymphoid

Burkitt Lymphoma, Recurrence, Neoplasm, Residual

NCT05219734 2024-03-12

MARIA

Invitae Corporation

Active not recruiting
400 enrolled
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Neoplasm, Residual

NCT03459170 2022-07-12

Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant

Bellicum Pharmaceuticals

Phase 1 Active not recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Leukemia, Lymphoma, Myelodysplastic Syndromes, Neoplasm, Residual, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡